In conversation with... Alexandra Durr episode artwork

EPISODE · Feb 22, 2022 · 7 MIN

In conversation with... Alexandra Durr

from Listen to The Lancet Neurology · host The Lancet

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

NOW PLAYING

In conversation with... Alexandra Durr

0:00 7:55

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Listen to The Lancet Neurology?

This episode is 7 minutes long.

When was this Listen to The Lancet Neurology episode published?

This episode was published on February 22, 2022.

What is this episode about?

Alexandra Durr (Paris Brain Institute, Pitié-Salpêtrière Paris, France) discusses the ATRIL study, a randomised trial of riluzole in patients with spinocerebellar ataxia type 2, which is published in the March issue of The Lancet Neurology.

Can I download this Listen to The Lancet Neurology episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!